Dive Brief:
- Senseonics has struck a deal to retake control of the commercialization and distribution of its implantable continuous glucose monitors, the company said Wednesday.
- Ascensia Diabetes Care is currently the exclusive worldwide distributor of the Eversense devices. That will change at the start of 2026, when Senseonics will resume responsibility.
- BTIG analysts said in a note to investors that the move shows “Senseonics is doubling down on its view that the one-year sensor will finally enable an inflection in patient demand for the implantable glucose monitor.”
Dive Insight:
Senseonics entered into a collaboration with Ascensia in 2020. The arrangement freed Senseonics from the need to establish and maintain commercial infrastructure but also required it to pay a revenue share to Ascensia.
Under the new agreement, U.S. commercial operations will transfer to Senseonics at the start of 2026. Senseonics CEO Tim Goodnow discussed the rationale for the deal on a call with investors, explaining that it will enable a “clear focus and targeted resourcing” to build the Eversense brand.
“Through this standalone strategy, we will recognize margin expansion and recaptured revenue share, which we expect will enable us to make the necessary strategic investment to drive awareness and adoption to accelerate Eversense penetration and revenue growth,” Goodnow said.
Senseonics expects gross margins to expand from around 35% at the midpoint of the range for this year to 50% in 2026. The company sees margins expanding to 70% in the future. However, BTIG analysts said there are additional costs to consider.
“We wonder how much of these savings will be offset by the operating expenses needed to support the sales organization and commercial efforts,” the analysts wrote. “In our view, Senseonics will need a large, high-touch salesforce and marketing teams to be successful in taking meaningful share from legacy systems or to expand the CGM-using population.”
Brian Hansen, the president of CGM at Ascensia, will become Senseonics’ chief commercial officer. BTIG analysts said the majority of the Ascensia U.S. sales and marketing teams have committed to joining Senseonics “and should enable a relatively smooth transition.”
The transfer comes as Senseonics continues to roll out its one-year Eversense 365 CGM implant in the U.S. The company has identified the longer lifespan of the device compared to older Eversense models as a development that can help it win share in a market dominated by Abbott and Dexcom.
